Trial reportCritical care (London, England)2013
Effect of erythropoietin on the incidence of acute kidney injury following complex valvular heart surgery: a double blind, randomized clinical trial of efficacy and safety.
Trial report in Critical care (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 22 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Erythropoietin on the Incidence of Acute Kidney Injury Following Complex Valvular Heart Surgery
The Prevention of Erythropoietin on Cardiac Surgery-associated Acute Kidney Injury
Who cites it
22 citing papers in PubMed, 5 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Erythropoiesis-stimulating agents for preventing acute kidney injury.The Cochrane database of systematic reviews · 2024Pooled it
- Harms of off-label erythropoiesis-stimulating agents for critically ill people.The Cochrane database of systematic reviews · 2017Pooled it
- Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017 : Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine.Intensive care medicine · 2017Pooled it
- Erythropoiesis stimulating agents and reno-protection: a meta-analysis.BMC nephrology · 2017Pooled it
- Efficacy and Safety of Erythropoietin to Prevent Acute Kidney Injury in Patients With Critical Illness or Perioperative Care: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Journal of cardiovascular pharmacology · 2015Pooled it
- Erythropoietin in Acute Kidney Injury (EAKI): a pragmatic randomized clinical trial.BMC nephrology · 2022Trial
- Effects of Erythropoietin on Lung Injury Induced by Cardiopulmonary Bypass After Cardiac Surgery.Medical science monitor : international medical journal of experimental and clinical research · 2020Trial
- Effects of erythropoietin administration on allogeneic blood transfusion requirements in adults undergoing surgery: a systematic review and meta-analysis.Frontiers in medicine · 2025Review
- Endocrinological disorders in acute kidney injury: an often overlooked field of clinical research.Journal of nephrology · 2023Review
- Disruption of Kidney-Immune System Crosstalk in Sepsis with Acute Kidney Injury: Lessons Learned from Animal Models and Their Application to Human Health.International journal of molecular sciences · 2022Review
- Targeting the innate repair receptor axisFrontiers in immunology · 2022Article
- Strategies for post-cardiac surgery acute kidney injury prevention: A network meta-analysis of randomized controlled trials.Frontiers in cardiovascular medicine · 2022Article
- Erythropoietin Attenuates Experimental Contrast-Induced Nephrology: A Role for the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Signaling Pathway.Frontiers in medicine · 2021Article
- Effects of early high-dose erythropoietin on acute kidney injury following cardiac arrest: exploratoryClinical kidney journal · 2020Article
- Acute kidney injury in hospitalized patients who underwent percutaneous kidney biopsy for histological diagnosis of their renal disease.BMC nephrology · 2019Article
- Effects of erythropoietin receptor activity on angiogenesis, tubular injury, and fibrosis in acute kidney injury: a "U-shaped" relationship.American journal of physiology. Renal physiology · 2018Article
- Erythropoietin stimulates the coronary collateral development in patients with coronary chronic total occlusion.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2016Article
- Prevention and Treatment of Cardiac Surgery Associated Acute Kidney Injury.Journal of anesthesia and perioperative medicine · 2016Article
- Bridging Translation by Improving Preclinical Study Design in AKI.Journal of the American Society of Nephrology : JASN · 2015Review
- Molecular mechanisms of ischemic preconditioning in the kidney.American journal of physiology. Renal physiology · 2015Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRecombinant human erythropoietin (EPO) is known to provide organ protection against ischemia-reperfusion injury through its pleiotropic properties. The aim of this single-site, randomized, case-controlled, and double-blind study was to investigate the effect of pre-emptive EPO administration on the incidence of postoperative acute kidney injury (AKI) in patients with risk factors for AKI undergoing complex valvular heart surgery.
methodsWe studied ninety-eight patients with preoperative risk factors for AKI. The patients were randomly allocated to either the EPO group (n = 49) or the control group (n = 49). The EPO group received 300 IU/kg of EPO intravenously after anesthetic induction. The control group received an equivalent volume of normal saline. AKI was defined as an increase in serum creatinine >0.3 mg/dl or >50% from baseline. Biomarkers of renal injury were serially measured until five days postoperatively.
resultsPatient characteristics and operative data, including the duration of cardiopulmonary bypass, were similar between the two groups. Incidence of postoperative AKI (32.7% versus 34.7%, P = 0.831) and biomarkers of renal injury including cystatin C and neutrophil gelatinase-associated lipocalin showed no significant differences between the groups. The postoperative increase in interleukin-6 and myeloperoxidase was similar between the groups. None of the patients developed adverse complications related to EPO administration, including thromboembolic events, throughout the study period.
conclusionsIntravenous administration of 300 IU/kg of EPO did not provide renal protection in patients who are at increased risk of developing AKI after undergoing complex valvular heart surgery.
trial registrationClinical Trial.gov, NCT01758861.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.